Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Benedicte Lebreton
Advertisement
Benedicte Lebreton is a scientist, early-stage purification, at Genentech, Inc.
Articles by Benedicte Lebreton
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Welcome to CPHI Frankfurt 2025
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
